ConductScience.org, home

Paper32199199

miR-504 expression level is increased in multiple sclerosis patients responder to interferon-beta.

Tahmasebivand M and 8 others. J Neuroimmunol, 2020. Cited by 10 papers, by iCite.

Cite this record

ConductScience Library. miR-504 expression level is increased in multiple sclerosis patients responder to interferon-beta. Papers, record 32199199. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32199199

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
miR-504 expression level is increased in multiple sclerosis patients responder to interferon-beta.
PubMed
Journal
J Neuroimmunol
PubMed
Year
2020
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
0.56
iCite
Revised in PubMed
2024-02-27
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tahmasebivand MMahsa
2Mousavi SRSeyyed Reza
3Khorrami MMehdi
4Ayromlou HHormoz
5Rikhtegar RReza
6Saberi LLeila
7Khademi BBahareh
8Bahmanpour ZZahra
9Emamalizadeh BBabak

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
42511484MicroRNA Expression Profiles as Biomarkers of Response to Disease-Modifying Therapies in Multiple Sclerosis: A Systematic Review.Int J Mol Sci2026https://conductscience.org/library/papers/42511484PubMed
37893133MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate.Biomedicines2023https://conductscience.org/library/papers/37893133PubMed
35774792microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate.Front Immunol2022https://conductscience.org/library/papers/35774792PubMed
34938929Scavenging the hidden impacts of non-coding RNAs in multiple sclerosis.Noncoding RNA Res2021https://conductscience.org/library/papers/34938929PubMed
33867350MicroRNA-532-5p protects against cerebral ischemia-reperfusion injury by directly targeting CXCL1.Aging (Albany NY)2021https://conductscience.org/library/papers/33867350PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
IFNB13456PubTator's text mininghttps://conductscience.org/library/genes/3456NCBI Gene
MIR504574507PubTator's text mininghttps://conductscience.org/library/genes/574507NCBI Gene
MIR711100313843PubTator's text mininghttps://conductscience.org/library/genes/100313843NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32199199

GET https://conductscience.org/api/papers/v1/32199199/authors